Imaging Core Lab for Boehringer Ingelheim Phase IIIb study of BI-456906 (BOI01)

Imaging Core Lab for Boehringer Ingelheim Phase IIIb study of BI-456906 (BOI01)

Es posible que algunos contenidos no estén disponibles en español.

Study Details

Full Title

A multicentre, randomised, double-blind, placebo-controlled 52 week, Phase IIIb trial to evaluate the efficacy and safety of survodutide in peri- and post menopausal women with overweight or obesity (SYNCHRONIZE-HERA)

Principal Investigator

Mustafa
Bashir

Protocol Number

PRO00120627

Phase

N/A

Enrollment Status

Open to Enrollment